|Source:||The roots of Panax ginseng C. A. Mey.|
|Biological Activity or Inhibitors:||1. Ginsenoside Rh1 displays hypoallergenic and antiinflammatory properties, via its cell membrane-stabilizing and anti-inflammatory activities which reduction of IgE and IL-6 levels in peripheral blood and increase of Foxp3 expression in draining lymph nodes and suppression of inflammation in skin regions.
2. Ginsenoside Rh1 is a weak phytoestrogen, presumably by binding and activating the estrogen receptor.
|Solvent:||Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.5652 mL||7.8262 mL||15.6524 mL||31.3048 mL||39.131 mL|
|5 mM||0.313 mL||1.5652 mL||3.1305 mL||6.261 mL||7.8262 mL|
|10 mM||0.1565 mL||0.7826 mL||1.5652 mL||3.1305 mL||3.9131 mL|
|50 mM||0.0313 mL||0.1565 mL||0.313 mL||0.6261 mL||0.7826 mL|
|100 mM||0.0157 mL||0.0783 mL||0.1565 mL||0.313 mL||0.3913 mL|
Evid Based Complement Alternat Med. 2015;2015:727650.
|Ginsenoside Rh1 Improves the Effect of Dexamethasone on Autoantibodies Production and Lymphoproliferation in MRL/lpr Mice.[Pubmed: 25918545]|
|Ginsenoside Rh1 is able to upregulate glucocorticoid receptor (GR) level, suggesting Ginsenoside Rh1 may improve glucocorticoid efficacy in hormone-dependent diseases. Therefore, we investigated whether Ginsenoside Rh1 could enhance the effect of dexamethasone (Dex) in the treatment of MRL/lpr mice. MRL/lpr mice were treated with vehicle, Dex, Ginsenoside Rh1, or Dex + Rh1 for 4 weeks. Dex significantly reduced the proteinuria and anti-dsDNA and anti-ANA autoantibodies. The levels of proteinuria and anti-dsDNA and anti-ANA autoantibodies were further decreased in Dex +Ginsenoside Rh1 group. Dex, Ginsenoside Rh1, or Dex +Ginsenoside Rh1 did not alter the proportion of CD4+ splenic lymphocytes, whereas the proportion of CD8+ splenic lymphocytes was significantly increased in Dex and Dex +Ginsenoside Rh1 groups. Dex +Ginsenoside Rh1 significantly decreased the ratio of CD4+/CD8+ splenic lymphocytes compared with control. Con A-induced CD4+ splenic lymphocytes proliferation was increased in Dex-treated mice and was inhibited in Dex + Ginsenoside Rh1-treated mice. Th1 cytokine IFN-γ mRNA was suppressed and Th2 cytokine IL-4 mRNA was increased by Dex. The effect of Dex on IFN-γ and IL-4 mRNA was enhanced by Ginsenoside Rh1. In conclusion, our data suggest that Rh1 may enhance the effect of Dex in the treatment of MRL/lpr mice through regulating CD4+ T cells activation and Th1/Th2 balance.|
J Pharm Pharmacol. 2014 Dec;66(12):1763-73.
|Ginsenoside Rh1 induces mouse osteoblast growth and differentiation through the bone morphogenetic protein 2/runt-related gene 2 signalling pathway.[Pubmed: 25154440]|
|This study aimed to investigate the stimulative and pharmacological effects of Ginsenoside Rh1 (hereinafter referred to as: Ginsenoside Rh1) on differentiation and mineralization of osteoblast and its possible mechanism of action on the expression of bone morphogenetic protein 2 (BMP-2)/Runt-related gene 2 (Runx2) signalling pathways using mouse preosteoblastic MC3T3-E1 cell line as in-vitro model. Ginsenoside Rh1 was capable to stimulate cell growth, ALP activity, Coll-I synthesis, mineralization and glutathione content in the MC3T3-E1 cells. BMP-2 and Runx2 expression were also increased by Ginsenoside Rh1 concentration dependently. Additionally, Ginsenoside Rh1 also showed inhibitory action on the level of ROS production enhanced by AMA in MC3T3-E1 cells. Ginsenoside Rh1 could increase the expression level of BMP-2/Runx2 signal-regulated osteogenic markers such as ALP, Coll-I and OCN. Ginsenoside Rh1, a protopanaxatriol type's active ingredients of Panax ginseng Meyer, possesses osteoblast differentiation, osteogenic stimulatory and anti-oxidative activity.|
Arthritis Res Ther. 2014 May 1;16(3):R106.
|Ginsenoside Rh1 potentiates dexamethasone's anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance.[Pubmed: 24887434]|
|We sought to unravel how a plant-original compound, Ginsenoside Rh1, potentiates dexmethasone (DEX)'s potential anti-inflammation properties. METHODS: Ginsenoside Rh1 potentiates DEX's anti-inflammatory effects even after prolonged DEX treatment. Ginsenoside Rh1 could improve the glucocorticoid receptor (GR)'s transrepression on nuclear factor kappa B (NF-κB) and transactivation on dual specificity protein phosphatase 1 (DUSP1), which is responsible for DEX's anti-inflammatory effects. Parallel Western blot assay and radioligand binding analysis revealed that Ginsenoside Rh1 could increase the expression and binding of GR. This is in sharp contrast to DEX alone, showing a direct link among prolonged treatment, decreasing GR and the abolishment of anti-inflammation. Interestingly,Ginsenoside Rh1 does not enhance the transactivation of glucocorticoid-responsive elements (GRE) driven genes - gluconeogenic enzyme glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinasee phosphatase (PEPCK) in primary mouse hepatocytes, a mechanism partly held accountable for the metabolic side-effects. Similar results were found in CIA mice. Ginsenoside Rh1 could potentiate DEX's anti-inflammatory effects and does not cause a hyperglycemic side effect. Ginsenoside Rh1 combined with DEX may be a promising candidate treatment option for chronic inflammatory diseases in need of long-term immunosuppression therapies.|
Int J Mol Med. 2014 Jan;33(1):234-40.
|Long-term administration of ginsenoside Rh1 enhances learning and memory by promoting cell survival in the mouse hippocampus.[Pubmed: 24212564]|
|In this study, to investigate the beneficial effects of Ginsenoside Rh1 on hippocampal cells and learning, mice (6 months old) were administered Ginsenoside Rh1 at a dose of 5 and 10 mg/kg/day for a period of 3 months. Saline-treated mice were used as controls. The enhancement of memory and learning in the mice was evaluated by hippocampal-dependent tasks (passive avoidance tests and Morris water maze tests) and the immunohistochemical marker of cell proliferation, bromodeoxyuridine (BrdU). In addition, the levels of brain-derived neurotrophic factor (BDNF) were measured following treatment. Based on our data, the Ginsenoside Rh1-treated group (5 and 10 mg/kg) showed a significantly improved learning and memory ability in the passive avoidance tests compared with the control group; however, only treatment with 10 mg/kg Ginsenoside Rh1 significantly promoted spatial learning ability in the Morris water maze test. Ginsenoside Rh1 significantly enhanced cell survival in the dentate gyrus of mice, although it did not enhance hippocampal cell proliferation. In addition, Ginsenoside Rh1 upregulated the expression of BDNF. These findings address the potential therapeutic significance of Ginsenoside Rh1 as a nutritional supplement in memory loss and neurodegenerative diseases.|